LOSS OF HBsAg WITH INTERFERON THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
46 male chronic hepatitis B virus (HBV) carriers with active viral replication were randomised, with stratification for histology and sexual preference, to receive six months' lymphoblastoid interferon or no therapy. After nine to eighteen months' follow-up, HBeAg was no longer detectable...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 1987-07, Vol.330 (8550), p.66-69 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 69 |
|---|---|
| container_issue | 8550 |
| container_start_page | 66 |
| container_title | The Lancet (British edition) |
| container_volume | 330 |
| creator | Alexander, GraemeJ.M. Fagan, ElizabethA Daniels, HelenaM Brahm, Javier Smith, HeatherM Eddleston, AdrianL.W.F. Williams, Koger |
| description | 46 male chronic hepatitis B virus (HBV) carriers with active viral replication were randomised, with stratification for histology and sexual preference, to receive six months' lymphoblastoid interferon or no therapy. After nine to eighteen months' follow-up, HBeAg was no longer detectable and anti-HBe was present in 6 of the 23 treated patients. HBsAg was not detectable in 5 of these patients and 3 had anti-HBs. All of the controls remained positive for HBeAg and HBsAg. Seroconversion from HBeAg to anti-HBe was preceded in all cases by a pronounced increase in serum aspartate aminotransferase levels of more than ten times the upper limit of normal at eight to twelve weeks; this response was exclusively associated with interferon therapy. These results suggest that loss of HBsAg and a hepatitis-like illness in the third month of therapy are direct effects of interferon treatment. |
| doi_str_mv | 10.1016/S0140-6736(87)92735-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2138598041</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673687927358</els_id><sourcerecordid>2138598041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c250t-178d073be2e4d8235c8fb064c1ac1a879d40ebe9845f8ab7da6922284bef8a123</originalsourceid><addsrcrecordid>eNqFUF1LwzAUDaLgnP4EIeCLPlSTNGnSJ6mltYWyjrbz4yn0I5UOXWeyCf57s018FS5c7rnnnMs9AFxidIsR9u5KhClyPO5614Lf-IS7zBFHYIIppw6j_OUYTP4op-DMmCVCiHqITUCW5WUJ8xgmDyZ4g89plcB0VkVFHBX5DFZJVATzVwvBMLFAGsIkmgdVWqUlfIBPabEo7TKOwirNZ-fgpK_fjbr47VOwiKMqTJwsf0zDIHNawtDGwVx0iLuNIop2grisFX2DPNri2pbgfkeRapQvKOtF3fCu9nxCiKCNsjMm7hRcHXzXevzcKrORy3GrV_akJNgVzBeIYstiB1arR2O06uVaDx-1_pYYyV1wch-c3KUiBZf74KSwuvuDTtkXvgalpWkHtWpVN2jVbmQ3Dv84_AD00G2z</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2138598041</pqid></control><display><type>article</type><title>LOSS OF HBsAg WITH INTERFERON THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION</title><source>Elsevier ScienceDirect Journals</source><creator>Alexander, GraemeJ.M. ; Fagan, ElizabethA ; Daniels, HelenaM ; Brahm, Javier ; Smith, HeatherM ; Eddleston, AdrianL.W.F. ; Williams, Koger</creator><creatorcontrib>Alexander, GraemeJ.M. ; Fagan, ElizabethA ; Daniels, HelenaM ; Brahm, Javier ; Smith, HeatherM ; Eddleston, AdrianL.W.F. ; Williams, Koger</creatorcontrib><description>46 male chronic hepatitis B virus (HBV) carriers with active viral replication were randomised, with stratification for histology and sexual preference, to receive six months' lymphoblastoid interferon or no therapy. After nine to eighteen months' follow-up, HBeAg was no longer detectable and anti-HBe was present in 6 of the 23 treated patients. HBsAg was not detectable in 5 of these patients and 3 had anti-HBs. All of the controls remained positive for HBeAg and HBsAg. Seroconversion from HBeAg to anti-HBe was preceded in all cases by a pronounced increase in serum aspartate aminotransferase levels of more than ten times the upper limit of normal at eight to twelve weeks; this response was exclusively associated with interferon therapy. These results suggest that loss of HBsAg and a hepatitis-like illness in the third month of therapy are direct effects of interferon treatment.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(87)92735-8</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Aspartate aminotransferase ; Chronic infection ; Hepatitis ; Hepatitis B ; Hepatitis B e antigen ; Hepatitis B surface antigen ; Histology ; Interferon ; Patients ; Seroconversion ; Therapy ; Viruses</subject><ispartof>The Lancet (British edition), 1987-07, Vol.330 (8550), p.66-69</ispartof><rights>1987</rights><rights>Copyright Elsevier Limited Jul 11, 1987</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c250t-178d073be2e4d8235c8fb064c1ac1a879d40ebe9845f8ab7da6922284bef8a123</citedby><cites>FETCH-LOGICAL-c250t-178d073be2e4d8235c8fb064c1ac1a879d40ebe9845f8ab7da6922284bef8a123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0140-6736(87)92735-8$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids></links><search><creatorcontrib>Alexander, GraemeJ.M.</creatorcontrib><creatorcontrib>Fagan, ElizabethA</creatorcontrib><creatorcontrib>Daniels, HelenaM</creatorcontrib><creatorcontrib>Brahm, Javier</creatorcontrib><creatorcontrib>Smith, HeatherM</creatorcontrib><creatorcontrib>Eddleston, AdrianL.W.F.</creatorcontrib><creatorcontrib>Williams, Koger</creatorcontrib><title>LOSS OF HBsAg WITH INTERFERON THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION</title><title>The Lancet (British edition)</title><description>46 male chronic hepatitis B virus (HBV) carriers with active viral replication were randomised, with stratification for histology and sexual preference, to receive six months' lymphoblastoid interferon or no therapy. After nine to eighteen months' follow-up, HBeAg was no longer detectable and anti-HBe was present in 6 of the 23 treated patients. HBsAg was not detectable in 5 of these patients and 3 had anti-HBs. All of the controls remained positive for HBeAg and HBsAg. Seroconversion from HBeAg to anti-HBe was preceded in all cases by a pronounced increase in serum aspartate aminotransferase levels of more than ten times the upper limit of normal at eight to twelve weeks; this response was exclusively associated with interferon therapy. These results suggest that loss of HBsAg and a hepatitis-like illness in the third month of therapy are direct effects of interferon treatment.</description><subject>Aspartate aminotransferase</subject><subject>Chronic infection</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B e antigen</subject><subject>Hepatitis B surface antigen</subject><subject>Histology</subject><subject>Interferon</subject><subject>Patients</subject><subject>Seroconversion</subject><subject>Therapy</subject><subject>Viruses</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><recordid>eNqFUF1LwzAUDaLgnP4EIeCLPlSTNGnSJ6mltYWyjrbz4yn0I5UOXWeyCf57s018FS5c7rnnnMs9AFxidIsR9u5KhClyPO5614Lf-IS7zBFHYIIppw6j_OUYTP4op-DMmCVCiHqITUCW5WUJ8xgmDyZ4g89plcB0VkVFHBX5DFZJVATzVwvBMLFAGsIkmgdVWqUlfIBPabEo7TKOwirNZ-fgpK_fjbr47VOwiKMqTJwsf0zDIHNawtDGwVx0iLuNIop2grisFX2DPNri2pbgfkeRapQvKOtF3fCu9nxCiKCNsjMm7hRcHXzXevzcKrORy3GrV_akJNgVzBeIYstiB1arR2O06uVaDx-1_pYYyV1wch-c3KUiBZf74KSwuvuDTtkXvgalpWkHtWpVN2jVbmQ3Dv84_AD00G2z</recordid><startdate>19870711</startdate><enddate>19870711</enddate><creator>Alexander, GraemeJ.M.</creator><creator>Fagan, ElizabethA</creator><creator>Daniels, HelenaM</creator><creator>Brahm, Javier</creator><creator>Smith, HeatherM</creator><creator>Eddleston, AdrianL.W.F.</creator><creator>Williams, Koger</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>ASE</scope><scope>C1K</scope><scope>FPQ</scope><scope>H94</scope><scope>K6X</scope><scope>K9.</scope><scope>KB~</scope><scope>M7N</scope><scope>NAPCQ</scope></search><sort><creationdate>19870711</creationdate><title>LOSS OF HBsAg WITH INTERFERON THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION</title><author>Alexander, GraemeJ.M. ; Fagan, ElizabethA ; Daniels, HelenaM ; Brahm, Javier ; Smith, HeatherM ; Eddleston, AdrianL.W.F. ; Williams, Koger</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c250t-178d073be2e4d8235c8fb064c1ac1a879d40ebe9845f8ab7da6922284bef8a123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Aspartate aminotransferase</topic><topic>Chronic infection</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B e antigen</topic><topic>Hepatitis B surface antigen</topic><topic>Histology</topic><topic>Interferon</topic><topic>Patients</topic><topic>Seroconversion</topic><topic>Therapy</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alexander, GraemeJ.M.</creatorcontrib><creatorcontrib>Fagan, ElizabethA</creatorcontrib><creatorcontrib>Daniels, HelenaM</creatorcontrib><creatorcontrib>Brahm, Javier</creatorcontrib><creatorcontrib>Smith, HeatherM</creatorcontrib><creatorcontrib>Eddleston, AdrianL.W.F.</creatorcontrib><creatorcontrib>Williams, Koger</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>British Nursing Index</collection><collection>Environmental Sciences and Pollution Management</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Newsstand Professional</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alexander, GraemeJ.M.</au><au>Fagan, ElizabethA</au><au>Daniels, HelenaM</au><au>Brahm, Javier</au><au>Smith, HeatherM</au><au>Eddleston, AdrianL.W.F.</au><au>Williams, Koger</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>LOSS OF HBsAg WITH INTERFERON THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION</atitle><jtitle>The Lancet (British edition)</jtitle><date>1987-07-11</date><risdate>1987</risdate><volume>330</volume><issue>8550</issue><spage>66</spage><epage>69</epage><pages>66-69</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><abstract>46 male chronic hepatitis B virus (HBV) carriers with active viral replication were randomised, with stratification for histology and sexual preference, to receive six months' lymphoblastoid interferon or no therapy. After nine to eighteen months' follow-up, HBeAg was no longer detectable and anti-HBe was present in 6 of the 23 treated patients. HBsAg was not detectable in 5 of these patients and 3 had anti-HBs. All of the controls remained positive for HBeAg and HBsAg. Seroconversion from HBeAg to anti-HBe was preceded in all cases by a pronounced increase in serum aspartate aminotransferase levels of more than ten times the upper limit of normal at eight to twelve weeks; this response was exclusively associated with interferon therapy. These results suggest that loss of HBsAg and a hepatitis-like illness in the third month of therapy are direct effects of interferon treatment.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><doi>10.1016/S0140-6736(87)92735-8</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 1987-07, Vol.330 (8550), p.66-69 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_journals_2138598041 |
| source | Elsevier ScienceDirect Journals |
| subjects | Aspartate aminotransferase Chronic infection Hepatitis Hepatitis B Hepatitis B e antigen Hepatitis B surface antigen Histology Interferon Patients Seroconversion Therapy Viruses |
| title | LOSS OF HBsAg WITH INTERFERON THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T07%3A04%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=LOSS%20OF%20HBsAg%20WITH%20INTERFERON%20THERAPY%20IN%20CHRONIC%20HEPATITIS%20B%20VIRUS%20INFECTION&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Alexander,%20GraemeJ.M.&rft.date=1987-07-11&rft.volume=330&rft.issue=8550&rft.spage=66&rft.epage=69&rft.pages=66-69&rft.issn=0140-6736&rft.eissn=1474-547X&rft_id=info:doi/10.1016/S0140-6736(87)92735-8&rft_dat=%3Cproquest_cross%3E2138598041%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2138598041&rft_id=info:pmid/&rft_els_id=S0140673687927358&rfr_iscdi=true |